Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.71 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566479 | 0.84 | S1PR1 (0.69) | S1PR1S1PR3 | |
| SCHEMBL566399 | 0.83 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL566042 | 0.83 | S1PR1 (1.00) | S1PR1S1PR3SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL566253 | 0.77 | S1PR1 (0.67) | S1PR1S1PR3SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL564960 | 0.76 | S1PR1 (0.70) | S1PR1S1PR3SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL177604 | 0.75 | S1PR1 (0.53) | S1PR1S1PR3SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13416834 | 0.75 | S1PR1 (1.00) | S1PR1S1PR3SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL566290 | 0.75 | S1PR1 (0.76) | S1PR1S1PR3 | |
| SCHEMBL4420175 | 0.75 | S1PR1 (0.64) | S1PR1S1PR3SMN1; SMN2MAPT | |
| SCHEMBL2122385 | 0.74 | S1PR1 (0.73) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR3 3/4885SMN1; SMN2 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.